APOTEX CORP. for APOTEX CORP.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
Federal policy relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; and Federal policy relating to providing incentives and federal funding to strengthen capabilities for domestic manufacturing of generic drugs.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Health Issues HCR
Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; and Federal policy relating to the structure of the Department of Health and Human Services.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Tariff (miscellaneous tariff bills) TAR
Executive Order 14231, Amendment to Duties To Address the Flow of Illicit Drugs Across our Northern Border, provisions relating to the imposition of tariffs on products from Canada and the exemption of pharmaceuticals from such tariffs; Executive Order 14257, Regulating Imports With A Reciprocal Tariff To Rectify Practices That Contribute To Large And Persistent Annual United States Goods Trade Deficits, provisions relating to the exemption of pharmaceuticals from reciprocal tariffs; Federal policy relating to the Department of Commerce's Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients [Docket No. 250414-006] and the exemption of pharmaceuticals compliant with the United States-Mexico-Canada trade agreement from any tariffs implemented following the completion of the Section 232 investigation;
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.